MRSA

Antimicrobials approved for children’s skin infectionsFor the first time in a decade, there are antibiotics newly approved for use in children with skin and skin structure infections that do not respond to conventional treatment.
Antibiotics improve outcomes in small skin abscessesAntibiotic treatment with either clindamycin or trimethoprim- sulfa - methoxazole (TMP-SMX) leads to better outcomes than incision and drainage with placebo in patients with uncomplicated cutaneous abscesses, particularly those caused by Staphylococcus aureus, according to a large study.
Pipeline antibiotic omadacycline shows promise against MRSA and morePhase 3 data for Paratek Pharmaceuticals’ once-daily treatment with IV-to-oral omadacycline has shown the pipeline drug effectively and safely treats the most frequently isolated bacterial pathogens associated with skin infections, including methicillin-resistant Staphylococcus aureus (MRSA)
Four steps managed care can take to promote antimicrobial stewardshipThe call for antimicrobial stewardship is growing. Enact these steps to prevent a return to the pre-antibiotic era.
Top 10 states with the highest hospital safety scoresThe Leapfrog Group recently released its latest hospital safety grades, and they indicate some interesting trends on a state-by-state basis.
New antibiotic for MRSA on the horizon
New antibiotic for MRSA on the horizonAs the healthcare profession continues to face challenges with antibiotic resistance, drugmakers are developing novel antibiotics that will be effective against some of the worst infections. One drugmaker submitted New Drug Applications (NDAs) for approval of IV and oral delafloxacin (Baxdela) to FDA.
Antibiotic resistance in the eyecare practiceFrom superbugs to MRSA, cautious antibiotic use can help
War on superbugs isn't overDespite improvements in the rates of healthcare associated infections in recent years, the Centers for Disease Control and Prevention says healthcare facilities still have more work to do to prevent sick patients from becoming sicker.
Skin bacteria may fuel cancer cell progressionA new study reveals that toxin-producing bacteria like staphylococcus may fuel CTCL; therefore, antibacterial treatment may slow disease progression. Findings could one day change how you treat patients.
Staphylococcus aureus infections in atopic dermatitisStaphylococcus aureus plays an important role in the pathogenesis and course of atopic dermatitis. Compared to the normal pediatric population, atopic patients are especially susceptible to colonization and recurrent infections of S aureus.